MAP3K12 and Parkinson disease: The inhibition of DLK has been proposed as a promising drug target to treat neurodegenerative diseases like amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease [1,2,4], glaucoma [7], and diabetes mellitus type 2 [8,9,10].